| Drug General Information |
| Drug ID |
D09ZAV
|
| Former ID |
DIB011339
|
| Drug Name |
RG-8803
|
| Synonyms |
Angiogenesis inhibitors, Repligen; BFGF inhibitors, Repligen; RG-8803B11; RGEN-1009; VEGF inhibitors, Repligen; 8803B11
|
| Indication |
Diabetic retinopathy [ICD9: 250.5; ICD10:H36, E10.3, E11.3, E13.3]
|
Terminated |
[1]
|
|---|
| Company |
Repligen Corp
|
| Target and Pathway |
| Target(s) |
Heparin-binding growth factor 2 |
Target Info |
Inhibitor |
[2]
|
|---|
| VEGF receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Melanomahsa04014:Ras signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
Endocytosis
|
|
Focal adhesion
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Integrins in angiogenesis
|
|
Syndecan-4-mediated signaling events
|
|
FGF signaling pathway
|
|
Reactome
|
PI3K Cascade
|
|
PIP3 activates AKT signaling
|
|
FGFR4 ligand binding and activation
|
|
FGFR3c ligand binding and activation
|
|
FGFR2c ligand binding and activation
|
|
FGFR2b ligand binding and activation
|
|
FGFR3 mutant receptor activation
|
|
Activated point mutants of FGFR2
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
|
|
Syndecan interactions
|
|
Non-integrin membrane-ECM interactions
|
|
Phospholipase C-mediated cascade: FGFR1
|
|
Phospholipase C-mediated cascade
|
|
Phospholipase C-mediated cascade
|
|
Phospholipase C-mediated cascade
|
|
SHC-mediated cascade:FGFR1
|
|
PI-3K cascade:FGFR1
|
|
FRS-mediated FGFR1 signaling
|
|
PI-3K cascade:FGFR2
|
|
SHC-mediated cascade:FGFR2
|
|
FRS-mediated FGFR2 signaling
|
|
SHC-mediated cascade:FGFR3
|
|
FRS-mediated FGFR3 signaling
|
|
PI-3K cascade:FGFR3
|
|
FRS-mediated FGFR4 signaling
|
|
SHC-mediated cascade:FGFR4
|
|
PI-3K cascade:FGFR4
|
|
Negative regulation of FGFR1 signaling
|
|
Negative regulation of FGFR2 signaling
|
|
Negative regulation of FGFR3 signaling
|
|
Negative regulation of FGFR4 signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Differentiation Pathway
|
|
Cardiac Hypertrophic Response
|
|
Syndecan interactions
|
|
Extracellular matrix organization
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Cardiac Progenitor Differentiation
|
|
Integrated Pancreatic Cancer Pathway
|
|
Neural Crest Differentiation
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
Signaling by FGFR
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158) |
|---|
| REF 2 | US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. |
|---|
